 Sarah Anderson
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 5 | 2020 | 1291 | 0.950 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2020 | 2531 | 0.830 |
Why?
| | Professional Role | 3 | 2020 | 167 | 0.820 |
Why?
| | Medication Therapy Management | 2 | 2020 | 76 | 0.760 |
Why?
| | Internship, Nonmedical | 1 | 2021 | 14 | 0.710 |
Why?
| | Pharmacists | 3 | 2022 | 265 | 0.700 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2021 | 82 | 0.680 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2014 | 165 | 0.660 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 83 | 0.630 |
Why?
| | Education, Pharmacy | 1 | 2021 | 120 | 0.620 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 58 | 0.600 |
Why?
| | Medication Reconciliation | 1 | 2018 | 29 | 0.570 |
Why?
| | Insulin, Long-Acting | 1 | 2017 | 63 | 0.550 |
Why?
| | 4-Hydroxycoumarins | 1 | 2016 | 4 | 0.520 |
Why?
| | Ambulatory Care | 1 | 2021 | 546 | 0.520 |
Why?
| | Dissociative Disorders | 1 | 2016 | 22 | 0.520 |
Why?
| | Vitamin K | 1 | 2016 | 45 | 0.510 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 445 | 0.490 |
Why?
| | Pharmacy Residencies | 1 | 2015 | 11 | 0.470 |
Why?
| | Atrial Fibrillation | 1 | 2019 | 388 | 0.460 |
Why?
| | Anticoagulants | 1 | 2019 | 664 | 0.450 |
Why?
| | Blood Coagulation Disorders | 1 | 2016 | 173 | 0.440 |
Why?
| | Dibenzothiazepines | 1 | 2014 | 17 | 0.440 |
Why?
| | Personnel Selection | 1 | 2015 | 78 | 0.440 |
Why?
| | Intrauterine Device Migration | 1 | 2013 | 3 | 0.430 |
Why?
| | Uterine Perforation | 1 | 2013 | 3 | 0.430 |
Why?
| | Patient Discharge | 2 | 2018 | 897 | 0.420 |
Why?
| | Levonorgestrel | 1 | 2013 | 38 | 0.420 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2013 | 29 | 0.410 |
Why?
| | Suicide, Attempted | 1 | 2016 | 378 | 0.400 |
Why?
| | Contraceptive Agents, Female | 1 | 2013 | 80 | 0.390 |
Why?
| | Venoms | 1 | 2012 | 29 | 0.390 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1040 | 0.380 |
Why?
| | Histamine H1 Antagonists | 1 | 2012 | 30 | 0.380 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 90 | 0.370 |
Why?
| | Specialization | 1 | 2013 | 144 | 0.370 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 194 | 0.370 |
Why?
| | Glucosides | 1 | 2012 | 44 | 0.370 |
Why?
| | Interviews as Topic | 1 | 2015 | 786 | 0.370 |
Why?
| | Administration, Oral | 3 | 2020 | 816 | 0.350 |
Why?
| | Stroke | 1 | 2019 | 1120 | 0.340 |
Why?
| | Postpartum Period | 1 | 2013 | 340 | 0.340 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 284 | 0.340 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 200 | 0.320 |
Why?
| | Pancreatitis | 1 | 2010 | 134 | 0.300 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2010 | 135 | 0.300 |
Why?
| | Patient-Centered Care | 1 | 2013 | 530 | 0.280 |
Why?
| | Peptides | 1 | 2012 | 985 | 0.250 |
Why?
| | Heart Failure | 1 | 2018 | 2236 | 0.220 |
Why?
| | Humans | 22 | 2022 | 137585 | 0.210 |
Why?
| | Aspirin | 2 | 2015 | 387 | 0.180 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2015 | 463 | 0.170 |
Why?
| | Education, Distance | 1 | 2021 | 50 | 0.170 |
Why?
| | Rural Health Services | 1 | 2021 | 128 | 0.160 |
Why?
| | Workflow | 1 | 2021 | 165 | 0.160 |
Why?
| | Middle Aged | 8 | 2020 | 33479 | 0.150 |
Why?
| | Cardiovascular System | 1 | 2020 | 137 | 0.140 |
Why?
| | Aged | 7 | 2020 | 23961 | 0.140 |
Why?
| | Heart Valve Diseases | 1 | 2019 | 151 | 0.140 |
Why?
| | Health Policy | 1 | 2021 | 388 | 0.140 |
Why?
| | Adult | 8 | 2021 | 37929 | 0.140 |
Why?
| | Antihypertensive Agents | 1 | 2021 | 494 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2014 | 1477 | 0.130 |
Why?
| | Cohort Studies | 2 | 2020 | 5742 | 0.130 |
Why?
| | Female | 11 | 2021 | 73304 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1050 | 0.120 |
Why?
| | Aged, 80 and over | 5 | 2016 | 7635 | 0.120 |
Why?
| | Pandemics | 2 | 2022 | 1639 | 0.120 |
Why?
| | Patient Transfer | 1 | 2018 | 176 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2016 | 5131 | 0.120 |
Why?
| | Body Weight | 1 | 2020 | 985 | 0.120 |
Why?
| | Heart Failure, Diastolic | 1 | 2015 | 21 | 0.120 |
Why?
| | Treatment Outcome | 2 | 2020 | 10811 | 0.110 |
Why?
| | Medically Underserved Area | 1 | 2015 | 85 | 0.110 |
Why?
| | Migraine Disorders | 1 | 2016 | 102 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 398 | 0.110 |
Why?
| | Quetiapine Fumarate | 1 | 2014 | 23 | 0.110 |
Why?
| | Hypertension | 2 | 2021 | 1295 | 0.110 |
Why?
| | Medical Marijuana | 1 | 2016 | 117 | 0.110 |
Why?
| | Eating | 1 | 2016 | 380 | 0.110 |
Why?
| | Schools, Pharmacy | 1 | 2013 | 47 | 0.100 |
Why?
| | Telephone | 1 | 2013 | 173 | 0.090 |
Why?
| | Blood Glucose | 2 | 2012 | 2186 | 0.090 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2012 | 30 | 0.090 |
Why?
| | Urban Population | 1 | 2015 | 479 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 862 | 0.090 |
Why?
| | Certification | 1 | 2013 | 113 | 0.090 |
Why?
| | Faculty | 1 | 2013 | 147 | 0.090 |
Why?
| | Benzhydryl Compounds | 1 | 2012 | 73 | 0.090 |
Why?
| | Acute Disease | 2 | 2015 | 1007 | 0.090 |
Why?
| | Male | 8 | 2020 | 67762 | 0.090 |
Why?
| | United States | 3 | 2021 | 14841 | 0.090 |
Why?
| | Nonprescription Drugs | 1 | 2012 | 63 | 0.090 |
Why?
| | Health Personnel | 1 | 2017 | 710 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 822 | 0.090 |
Why?
| | Bipolar Disorder | 1 | 2014 | 263 | 0.090 |
Why?
| | Risk | 1 | 2013 | 912 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2021 | 15657 | 0.090 |
Why?
| | Creatinine | 1 | 2012 | 499 | 0.080 |
Why?
| | Universities | 1 | 2013 | 433 | 0.080 |
Why?
| | Depressive Disorder, Major | 1 | 2014 | 364 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1066 | 0.080 |
Why?
| | Prospective Studies | 1 | 2020 | 7604 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 697 | 0.070 |
Why?
| | Length of Stay | 1 | 2013 | 1215 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2012 | 766 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 3457 | 0.070 |
Why?
| | Weight Loss | 1 | 2012 | 787 | 0.060 |
Why?
| | Hospitalization | 1 | 2015 | 2199 | 0.060 |
Why?
| | Young Adult | 3 | 2016 | 13209 | 0.050 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 92 | 0.040 |
Why?
| | Adolescent | 3 | 2016 | 21513 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 201 | 0.040 |
Why?
| | Primary Prevention | 1 | 2014 | 196 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 673 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5472 | 0.020 |
Why?
| | Animals | 1 | 2012 | 36940 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 698 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3295 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1357 | 0.020 |
Why?
| | Prevalence | 1 | 2013 | 2734 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 2111 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 10388 | 0.010 |
Why?
|
|
Anderson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|